BCYC vs. IMVT, APLS, VKTX, ACAD, CRNX, ZLAB, MTSR, DNLI, XENE, and MOR
Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
Bicycle Therapeutics vs.
Immunovant (NASDAQ:IMVT) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.
Bicycle Therapeutics received 11 more outperform votes than Immunovant when rated by MarketBeat users. However, 78.40% of users gave Immunovant an outperform vote while only 70.05% of users gave Bicycle Therapeutics an outperform vote.
Immunovant has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Immunovant's return on equity.
Immunovant currently has a consensus target price of $45.90, suggesting a potential upside of 118.61%. Bicycle Therapeutics has a consensus target price of $29.43, suggesting a potential upside of 150.88%. Given Bicycle Therapeutics' higher probable upside, analysts plainly believe Bicycle Therapeutics is more favorable than Immunovant.
47.1% of Immunovant shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.9% of Immunovant shares are held by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Immunovant has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Bicycle Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunovant had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Immunovant and 2 mentions for Bicycle Therapeutics. Immunovant's average media sentiment score of 1.16 beat Bicycle Therapeutics' score of 0.00 indicating that Immunovant is being referred to more favorably in the media.
Summary
Bicycle Therapeutics beats Immunovant on 10 of the 18 factors compared between the two stocks.
Get Bicycle Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicycle Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCYC) was last updated on 2/21/2025 by MarketBeat.com Staff
